Emergent BioSolutions Past Earnings Performance
Past criteria checks 0/6
Emergent BioSolutions's earnings have been declining at an average annual rate of -55.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 4.5% per year.
Key information
-55.2%
Earnings growth rate
-56.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 4.5% |
| Return on equity | -117.1% |
| Net Margin | -72.5% |
| Next Earnings Update | 01 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Emergent BioSolutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,049 | -760 | 368 | 0 |
| 30 Sep 23 | 1,103 | -778 | 372 | 0 |
| 30 Jun 23 | 1,072 | -602 | 368 | 0 |
| 31 Mar 23 | 979 | -403 | 356 | 0 |
| 31 Dec 22 | 1,118 | -212 | 340 | 0 |
| 30 Sep 22 | 1,491 | 33 | 341 | 0 |
| 30 Jun 22 | 1,581 | 88 | 341 | 0 |
| 31 Mar 22 | 1,757 | 158 | 352 | 0 |
| 31 Dec 21 | 1,774 | 220 | 349 | 0 |
| 30 Sep 21 | 1,653 | 227 | 336 | 0 |
| 30 Jun 21 | 1,709 | 299 | 330 | 0 |
| 31 Mar 21 | 1,706 | 387 | 315 | 0 |
| 31 Dec 20 | 1,577 | 306 | 304 | 0 |
| 30 Sep 20 | 1,333 | 167 | 289 | 0 |
| 30 Jun 20 | 1,259 | 170 | 278 | 0 |
| 31 Mar 20 | 1,108 | 68 | 273 | 0 |
| 31 Dec 19 | 1,106 | 55 | 274 | 0 |
| 30 Sep 19 | 1,016 | 4 | 278 | 0 |
| 30 Jun 19 | 878 | -18 | 255 | 0 |
| 31 Mar 19 | 855 | 42 | 223 | 0 |
| 31 Dec 18 | 782 | 63 | 203 | 0 |
| 30 Sep 18 | 706 | 100 | 163 | 0 |
| 30 Jun 18 | 681 | 113 | 156 | 0 |
| 31 Mar 18 | 562 | 67 | 148 | 0 |
| 31 Dec 17 | 561 | 83 | 143 | 0 |
| 30 Sep 17 | 519 | 81 | 131 | 0 |
| 30 Jun 17 | 512 | 68 | 133 | 0 |
| 31 Mar 17 | 503 | 61 | 137 | 0 |
| 31 Dec 16 | 489 | 63 | 143 | 0 |
| 30 Sep 16 | 497 | 73 | 139 | 0 |
| 30 Jun 16 | 512 | 94 | 128 | 0 |
| 31 Mar 16 | 529 | 125 | 119 | 0 |
| 31 Dec 15 | 489 | 91 | 121 | 0 |
| 30 Sep 15 | 478 | 79 | 110 | 0 |
| 30 Jun 15 | 457 | 59 | 115 | 0 |
| 31 Mar 15 | 460 | 35 | 119 | 0 |
| 31 Dec 14 | 404 | 54 | 109 | 0 |
| 30 Sep 14 | 400 | 22 | 109 | 0 |
| 30 Jun 14 | 351 | 14 | 101 | 0 |
| 31 Mar 14 | 324 | 19 | 91 | 0 |
| 31 Dec 13 | 313 | 31 | 85 | 0 |
| 30 Sep 13 | 309 | 32 | 82 | 0 |
| 30 Jun 13 | 287 | 25 | 79 | 0 |
Quality Earnings: ER4 is currently unprofitable.
Growing Profit Margin: ER4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ER4 is unprofitable, and losses have increased over the past 5 years at a rate of 55.2% per year.
Accelerating Growth: Unable to compare ER4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ER4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: ER4 has a negative Return on Equity (-117.13%), as it is currently unprofitable.